Form 4: Teva Executive VP Richard Daniell Acquires 183,169 Restricted Share Units

Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports acquisition of 183,169 restricted share units following performance criteria satisfaction.

Summary

• Richard Daniell, Executive VP of European Commercial at Teva Pharmaceutical Industries, filed a Form 4.
• The filing reports the acquisition of 183,169 restricted share units on January 28, 2025.
• These restricted share units were received upon meeting performance criteria of performance share units.
• The restricted share units are subject to time-based vesting and will vest on March 4, 2025.
• Each restricted share unit represents a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, as determined by the Human Resources and Compensation Committee.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard executive compensation transaction. The acquisition of shares based on performance is generally a positive sign, but it's a routine event.

Positives

• The acquisition of restricted share units suggests that performance criteria were met, which could be viewed positively.

Future Outlook

The restricted share units will vest on March 4, 2025, contingent on continued employment and potentially other factors.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include restricted share units as a way to align management's interests with those of shareholders.
• The vesting schedules and performance criteria associated with these units are typically benchmarked against those of peer companies to ensure competitiveness.

Stakeholder Impact

• The acquisition of restricted share units aligns the executive's interests with those of shareholders.

Key Dates